Haemonetics (HAE) Competitors $72.55 -0.90 (-1.23%) Closing price 03:59 PM EasternExtended Trading$71.74 -0.80 (-1.11%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HAE vs. DXCM, HQY, LNTH, PODD, QTRX, SIBN, PEN, ZBH, COO, and ALGNShould you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), Quanterix (QTRX), SiBone (SIBN), Penumbra (PEN), Zimmer Biomet (ZBH), Cooper Companies (COO), and Align Technology (ALGN). These companies are all part of the "medical" sector. Haemonetics vs. Its Competitors DexCom HealthEquity Lantheus Insulet Quanterix SiBone Penumbra Zimmer Biomet Cooper Companies Align Technology Haemonetics (NYSE:HAE) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment. Do analysts recommend HAE or DXCM? Haemonetics presently has a consensus price target of $97.30, suggesting a potential upside of 34.11%. DexCom has a consensus price target of $99.60, suggesting a potential upside of 18.73%. Given Haemonetics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Haemonetics is more favorable than DexCom.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Haemonetics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00DexCom 0 Sell rating(s) 4 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.91 Do insiders & institutionals have more ownership in HAE or DXCM? 99.7% of Haemonetics shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.8% of Haemonetics shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, HAE or DXCM? Haemonetics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Does the media refer more to HAE or DXCM? In the previous week, DexCom had 2 more articles in the media than Haemonetics. MarketBeat recorded 17 mentions for DexCom and 15 mentions for Haemonetics. DexCom's average media sentiment score of 1.36 beat Haemonetics' score of 0.43 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 12 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is HAE or DXCM more profitable? DexCom has a net margin of 12.90% compared to Haemonetics' net margin of 12.32%. DexCom's return on equity of 30.05% beat Haemonetics' return on equity.Company Net Margins Return on Equity Return on Assets Haemonetics12.32% 26.37% 9.22% DexCom 12.90%30.05%10.00% Which has stronger earnings and valuation, HAE or DXCM? DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHaemonetics$1.36B2.56$167.68M$3.3121.92DexCom$4.03B8.16$576.20M$1.3462.60 SummaryDexCom beats Haemonetics on 11 of the 16 factors compared between the two stocks. Get Haemonetics News Delivered to You Automatically Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HAE vs. The Competition Export to ExcelMetricHaemoneticsMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.53B$10.25B$5.54B$20.85BDividend YieldN/A2.06%3.75%3.65%P/E Ratio21.9211.7121.0126.34Price / Sales2.5630.03433.8159.22Price / Cash10.1922.3936.1622.29Price / Book4.443.578.124.66Net Income$167.68M$235.43M$3.25B$994.58M7 Day Performance-3.97%-1.67%0.97%-0.29%1 Month Performance3.65%2.91%7.36%4.91%1 Year Performance-16.21%-16.44%31.31%10.53% Haemonetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HAEHaemonetics4.8923 of 5 stars$72.55-1.2%$97.30+34.1%-18.7%$3.53B$1.36B21.923,023DXCMDexCom4.7868 of 5 stars$82.94+0.0%$98.50+18.8%-26.6%$32.52B$4.03B61.9010,300Positive NewsAnalyst ForecastHQYHealthEquity3.2199 of 5 stars$101.83-0.3%$118.09+16.0%+27.3%$8.83B$1.20B74.333,120Positive NewsAnalyst RevisionLNTHLantheus4.6279 of 5 stars$79.19-1.5%$130.50+64.8%-39.5%$5.56B$1.53B22.50700News CoveragePositive NewsAnalyst ForecastPODDInsulet4.5379 of 5 stars$300.70-0.1%$321.00+6.8%+43.4%$21.19B$2.07B54.083,900Analyst RevisionQTRXQuanterix2.8276 of 5 stars$6.30-9.7%$15.60+147.6%-65.0%$348.68M$137.42M-4.85460News CoverageAnalyst RevisionSIBNSiBone3.8824 of 5 stars$18.01-2.5%$22.50+24.9%-2.2%$787.09M$167.18M-28.14350PENPenumbra4.7589 of 5 stars$248.05-1.2%$302.40+21.9%+13.3%$9.72B$1.19B234.014,500ZBHZimmer Biomet4.9521 of 5 stars$92.58-1.2%$111.33+20.3%-14.5%$18.53B$7.68B20.4817,000Analyst UpgradeCOOCooper Companies3.1361 of 5 stars$73.290.0%$99.70+36.0%-19.5%$14.66B$3.90B35.5816,000Analyst ForecastHigh Trading VolumeALGNAlign Technology4.804 of 5 stars$193.83-1.5%$241.25+24.5%-23.3%$14.27B$4.00B35.3120,945Analyst Revision Related Companies and Tools Related Companies DexCom Alternatives HealthEquity Alternatives Lantheus Alternatives Insulet Alternatives Quanterix Alternatives SiBone Alternatives Penumbra Alternatives Zimmer Biomet Alternatives Cooper Companies Alternatives Align Technology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HAE) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.